Jefferies Group LLC set a $25.00 target price on RA PHARMCTL INC (NASDAQ:RARX) in a research note released on Friday morning. The brokerage currently has a buy rating on the stock.

Separately, Zacks Investment Research upgraded shares of RA PHARMCTL INC from a hold rating to a buy rating and set a $28.00 price target on the stock in a research report on Saturday, May 27th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. RA PHARMCTL INC has an average rating of Buy and a consensus target price of $27.00.

RA PHARMCTL INC (RARX) opened at 15.25 on Friday. The company’s market capitalization is $344.79 million. The stock’s 50 day moving average is $15.08 and its 200 day moving average is $20.21. RA PHARMCTL INC has a one year low of $12.05 and a one year high of $27.84.

RA PHARMCTL INC (NASDAQ:RARX) last announced its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.06. On average, analysts anticipate that RA PHARMCTL INC will post ($2.33) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/28/jefferies-group-llc-analysts-give-ra-pharmctl-inc-rarx-a-25-00-price-target.html.

In other RA PHARMCTL INC news, major shareholder Bioventures Ltd Novartis sold 19,647 shares of RA PHARMCTL INC stock in a transaction on Monday, June 5th. The shares were sold at an average price of $23.38, for a total transaction of $459,346.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 134,442 shares of company stock valued at $3,041,694 over the last ninety days. 14.50% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. American International Group Inc. purchased a new position in RA PHARMCTL INC during the first quarter valued at approximately $102,000. TIAA CREF Investment Management LLC raised its position in RA PHARMCTL INC by 97.0% in the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after buying an additional 3,859 shares during the last quarter. Alliancebernstein L.P. purchased a new position in RA PHARMCTL INC during the second quarter valued at approximately $195,000. Wells Fargo & Company MN raised its position in RA PHARMCTL INC by 151.8% in the first quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after buying an additional 5,700 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in RA PHARMCTL INC by 30.6% in the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after buying an additional 2,543 shares during the last quarter. 66.26% of the stock is owned by institutional investors.

RA PHARMCTL INC Company Profile

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Receive News & Stock Ratings for RA PHARMCTL INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RA PHARMCTL INC and related stocks with our FREE daily email newsletter.